Drug
OPC-67683 clinical trials
Also written Delamanid, OPC-67683 and Deltyba.
- studies test it
- 23
- open now
- 1
- in phase 3
- 7
- first study started
- 2006
Keep track of what changes. Save the OPC-67683 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 15
- Phase 3
- 7
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 14
Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Boston University (2) · Beijing Chest Hospital (2) · Médecins Sans Frontières, France (2) · Centers for Disease Control and Prevention (1) · Brigham and Women's Hospital (1) · Huashan Hospital (1)
Often tested with
Tested in the same studies.
Bedaquiline (10) · Linezolid (7) · Clofazimine (5) · Levofloxacin (5) · Pyrazinamide (5) · Moxifloxacin (3) · Quabodepistat (3) · Isoniazid (2)
Studies
Open first, then newest update. How each study uses OPC-67683 is read from its arms, and is right about nine times in ten.
Testing it · 23
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBRecruitingPhase 2University College, LondonNCT06114628Written as Delamanid (D)
- Short-course Regimens for the Treatment of Pulmonary TuberculosisActive, not recruitingPhase 2/3Centers for Disease Control and PreventionNCT05766267Written as Delamanid
- Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TBCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05221502Written as Delamanid
- Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TuberculosisActive, not recruitingPhase 2Brigham and Women's HospitalNCT05556746Written as Delamanid (DLM)
- Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TBActive, not recruitingPhase 2Boston UniversityNCT03828201Written as Delamanid
- Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIVCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03141060Written as Delamanid
- Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary TuberculosisCompletedPhase 2GlaxoSmithKlineNCT05382312Written as Delamanid
- Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese CohortActive, not recruitingPhase 3Huashan HospitalNCT06649721Written as delamanid
- Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis PatientsActive, not recruitingPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03568383Written as Delamanid (DLM)
- Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline CohortActive, not recruitingPhase 3Beijing Chest HospitalNCT06081361Written as Delamanid
- Evaluating Newly Approved Drugs for Multidrug-resistant TBCompletedPhase 3Médecins Sans Frontières, FranceNCT02754765Written as Delamanid
- Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)CompletedPhase 3Médecins Sans Frontières, FranceNCT03896685Written as Delamanid 50 MG Oral Tablet
- Treatment Shortening of MDR-TB Using Existing and New DrugsCompletedPhase 2Seoul National University HospitalNCT02619994Written as Delamanid
- A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary TuberculosisCompletedPhase 1/2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03678688Written as 30 mg OPC-167832 + 300 mg delamanid
- Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in ChinaStatus unknownPhase 4Beijing Chest HospitalNCT04421495Written as Delamanid
- Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary TuberculosisCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02583048Written as Delamanid
- A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)CompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT00685360Written as Delamanid
- Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive TuberculosisTerminatedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT01131351Written as Delamanid
- A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683CompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02573350Written as Delamanid
- A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)CompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT01859923Written as Delamanid
See all 23 studies that test OPC-67683 →
Given in every arm · 7 — OPC-67683 is usual care beside what is tested
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei ProvinceNot yet recruitingNot applicableWuhan Pulmonary HospitalNCT07198685Written as Delamanid (DLM)
- Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible TuberculosisNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07129629Written as Delamanid (D)
- BTZ-043 Dose Evaluation in Combination and SelectionCompletedPhase 2Michael HoelscherNCT05926466Written as Delamanid
- Linezolid Dosing Strategies in Drug-Resistant TBCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05007821Written as Delamanid 300 mg
- PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)CompletedPhase 2LigaChem Biosciences, Inc.NCT04550832Written as Bedaquiline, Delamanid, Moxifloxacin
- Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of CareCompletedPhase 3Wits Health Consortium (Pty) LtdNCT04062201Written as Delamanid in Oral Dosage Form
- PanACEA Sutezolid Dose-finding and Combination EvaluationCompletedPhase 2Michael HoelscherNCT03959566Written as Bedaquiline, Delamanid, Moxifloxacin
As the comparator · 3 — what is tested is compared with OPC-67683
- A Phase 2b Clinical Study of JDB0131 Benzenesulfonate TabletsRecruitingPhase 2WestVac Biopharma Co., Ltd.NCT07170800Written as Delamanid (D)
- A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant TuberculosisNot yet recruitingNot applicableWuhan Pulmonary HospitalNCT07126639Written as Delamanid (D)
- Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary TuberculosisRecruitingPhase 2Beijing Chest HospitalNCT06224036Written as Delamanid
Codes
What other systems call OPC-67683 · ClinicalTrials.gg INT005017
- MeSH (NLM) C516022OPC-67683One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C516022 | OPC-67683 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.